Revolution Medicines Strengthens Senior Management Team with Promotions and a New Hire
Revolution Medicines, Inc. (RVMD)
Company Research
Source: GlobeNewswire
Company Promotes Jack Anders to Chief Financial Officer and Jeff Cislini to General Counsel Daniel Simon to Join Company as Chief Business Officer REDWOOD CITY, Calif., Sept. 01, 2022 (GLOBE NEWSWIRE) -- Revolution Medicines, Inc. (Nasdaq: RVMD), a clinical-stage oncology company developing targeted therapies for RAS-addicted cancers, today announced two senior management promotions, as well as the addition of a new member to its leadership team. Jack Anders, who previously served as the company’s senior vice president, finance and principal financial and accounting officer, has been promoted to chief financial officer, and Jeff Cislini, formerly vice president, deputy general counsel, has been promoted to senior vice president, general counsel and corporate secretary. Additionally, Daniel Simon will join the company as chief business officer in early September. Mr. Anders has more than 20 years of finance and accounting experience. Since joining Revolution Medicines in 2018, he
Show less
Read more
Impact Snapshot
Event Time:
RVMD
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
RVMD alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
RVMD alerts
High impacting Revolution Medicines, Inc. news events
Weekly update
A roundup of the hottest topics
RVMD
News
- Revolution Medicines, Inc. (NASDAQ:RVMD) Q1 2024 Earnings Call Transcript [Yahoo! Finance]Yahoo! Finance
- Revolution Medicines, Inc. (NASDAQ: RVMD) had its price target raised by analysts at Wedbush from $42.00 to $46.00. They now have an "outperform" rating on the stock.MarketBeat
- Revolution Medicines, Inc. (NASDAQ: RVMD) had its "buy" rating re-affirmed by analysts at Needham & Company LLC. They now have a $46.00 price target on the stock.MarketBeat
- Revolution Medicines Reports First Quarter 2024 Financial Results and Update on Corporate Progress [Yahoo! Finance]Yahoo! Finance
- Revolution Medicines Reports First Quarter 2024 Financial Results and Update on Corporate ProgressGlobeNewswire
RVMD
Earnings
- 5/8/24 - Beat
RVMD
Sec Filings
- 5/8/24 - Form S-3ASR
- 5/8/24 - Form 10-Q
- 5/8/24 - Form 8-K
- RVMD's page on the SEC website